Quick answer: DHEA (dehydroepiandrosterone) is the most abundant circulating steroid hormone in humans, produced primarily by the adrenal zona reticularis, and serves as the obligate precursor for both testosterone and estradiol in peripheral tissues. DHEA-S (DHEA-sulfate, the circulating storage form) peaks at approximately 250-400 mcg/dL in men and 150-300 mcg/dL in women around ages 20-25, then declines 2-3% per year — falling to 10-20% of peak levels by age 70 (Orentreich 1984 — the original adrenopause paper). DHEA supplementation at 25-100mg/day has RCT evidence for bone density preservation, lean mass maintenance, mood improvement, and sexual function in older adults with documented DHEA deficiency. The key clinical distinction: DHEA replacement in deficiency is evidence-based; DHEA supplementation in individuals with normal DHEA-S is unsupported and carries androgen excess risks.
DHEA Physiology: The Adrenal Mother Hormone
DHEA is synthesized in the adrenal cortex zona reticularis through a multi-step pathway from cholesterol: cholesterol → pregnenolone (CYP11A1) → 17α-hydroxypregnenolone (CYP17A1 17α-hydroxylase) → DHEA (CYP17A1 17,20-lyase activity). The 17,20-lyase activity of CYP17A1 — the step that produces DHEA rather than cortisol precursors — is uniquely stimulated by the cytochrome b5 cofactor, which is expressed predominantly in the zona reticularis and not the zona fasciculata. This accounts for the adrenal zonation that produces either cortisol (zona fasciculata) or DHEA (zona reticularis) from the same CYP17A1 enzyme.
DHEA itself has low androgen receptor affinity — it functions primarily as a prohormone. In peripheral tissues, DHEA is converted by tissue-specific steroidogenic enzymes to testosterone (via 3β-HSD and 17β-HSD), estradiol (via aromatase from androstenedione), DHT (via 5α-reductase from androstenedione → testosterone → DHT), and 7α-hydroxy-DHEA (a unique neurosteroid metabolite with PPAR activity). This peripheral intracrine metabolism means that DHEA’s biological effects are tissue-specific — the same DHEA dose produces different androgen/estrogen balances in different tissues depending on local enzyme expression. This is why oral DHEA supplementation is difficult to predict without measuring downstream metabolites — a key role for DUTCH Complete testing.
DHEA-S (DHEA-sulfate) is the dominant circulating form — approximately 300-500 times higher in concentration than unconjugated DHEA — produced by SULT2A1 sulfotransferase in the adrenal cortex and liver. DHEA-S has a plasma half-life of 7-10 hours, making it a stable circulating reservoir that maintains constant DHEA supply to peripheral tissues. DHEA-S is the standard laboratory measurement and is used to assess adrenal androgen production and monitor supplementation.
The Adrenopause: DHEA Decline and Clinical Consequences
The age-related decline in DHEA-S — termed “adrenopause” — is among the most dramatic hormonal changes in human aging. Unlike gonadal sex hormones (where decline occurs at specific life transitions — menopause, andropause), DHEA decline is a continuous, linear process beginning in the mid-twenties and proceeding throughout life. By age 70, DHEA-S levels are approximately 20% of the values seen at peak production in young adulthood. By age 80-90, DHEA-S may fall to 5-10% of peak values.
The Rancho Bernardo Study (Barrett-Connor 1986, NEJM) established DHEA-S as an independent inverse predictor of cardiovascular mortality in men — men with DHEA-S in the highest quartile had 36% lower cardiovascular mortality than those in the lowest quartile, independent of age, obesity, lipids, and blood pressure. Subsequent studies extended this association to all-cause mortality, bone density, cognitive function, insulin sensitivity, and immune function. DHEA-S below 100 mcg/dL in women and below 150 mcg/dL in men are commonly used functional medicine thresholds indicating clinically significant deficiency requiring consideration of replacement.
Physiologically, DHEA-S declines accelerate under conditions of chronic HPA axis activation — chronic stress, inflammatory disease, sleep deprivation, and metabolic dysfunction all suppress zona reticularis function preferentially. The ratio of cortisol:DHEA-S is an important clinical marker: in healthy young adults, this ratio is approximately 5-10:1. In chronic stress, burnout, and HPA dysfunction states, this ratio rises to 20-50:1 as cortisol is maintained or elevated while DHEA-S falls. DUTCH Complete urinary hormone testing measures both cortisol metabolites and DHEA-S, providing the cortisol:DHEA ratio needed to characterize adrenal function and guide replacement decisions. For a detailed discussion of cortisol dynamics, see our cortisol awakening response article.
DHEA Supplementation: Evidence from Randomized Controlled Trials
The clinical evidence for DHEA supplementation is most robust in older adults with documented deficiency. Key RCTs by indication:
Bone density and body composition (DHEA-IT/DHEAge study): Villareal 2004 (JAMA, n=56 older adults aged 65-78, 50mg DHEA/day for 6 months) found significant increases in bone mineral density (lumbar spine and femoral neck) and lean mass, with reduction in fat mass, in both men and women. The effect was attributable to DHEA’s peripheral conversion to testosterone and estradiol, both of which independently support bone density. Jankowski 2006 extended the Villareal data to 12 months with continued bone density improvement.
Sexual function in women with adrenal insufficiency: Arlt 1999 (NEJM, n=24, double-blind crossover, 50mg DHEA/day for 4 months) — women with adrenal insufficiency on full cortisol and mineralocorticoid replacement but no sex hormone replacement showed significant improvements in well-being, depression, anxiety, and sexual function with DHEA vs placebo. This trial established DHEA as a critical missing component of adrenal insufficiency hormone replacement that standard hydrocortisone/fludrocortisone therapy does not address.